CD274 and neoplasm: Beyond traditional protein biomarkers like PD-L1, TMB, MSI-H, and dMMR [58, 100–102], circRNAs have emerged as innovative biomarkers for tumor immunotherapy, offering potential targets due to their stability in body fluids and specificity across tissues and developmental stages [103].